VA and DoD ordered to offer experimental nerve-block PTSD treatment to veterans
H.R. 1947 — TREAT PTSD Act · Filed by Scott Perry (R-PA) · 14 cosponsors · Introduced Mar 6, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Department of Veterans Affairs and Department of Defense to offer stellate ganglion block (SGB)—a nerve-blocking injection used experimentally to treat PTSD symptoms—to eligible veterans and active-duty service members who have been diagnosed with PTSD and consent to the procedure. The VA and DoD must also update their joint clinical practice guidelines within 180 days to reflect SGB as a therapy option and inform Congress of the update.
Why we flagged it
The bill's sole operative mechanism is to expand access to a specific medical treatment (stellate ganglion block) for a defined population (veterans and service members with PTSD) through existing federal healthcare systems. It is a straightforward healthcare access measure.
What the text implies
- SGB is an emerging/experimental treatment for PTSD with mixed evidence; widespread VA/DoD adoption may increase demand for a procedure that remains under clinical investigation, potentially affecting resource allocation within military healthcare.
- The 180-day guideline update requirement creates a tight timeline for VA/DoD to integrate SGB into clinical practice; implementation delays or incomplete guidance could create inconsistent access across facilities.
- Bill does not specify funding mechanism or appropriations; cost absorption by VA/DoD budgets may displace other PTSD treatments or mental health services if no new funding is provided.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Veterans and active-duty service members with PTSD gain access to an emerging treatment option at no personal cost, with informed consent protections. The bill expands therapeutic choice without restricting existing treatments or imposing costs on the broader public.
Who stands to gain
- medical device/pharmaceutical companies manufacturing or supplying stellate ganglion block materials
- healthcare providers and anesthesiologists trained to administer SGB
Named in the bill
Department of Veterans Affairs, Department of Defense, TRICARE, VA/DOD Clinical Practice Guideline for PTSD, House Committee on Veterans' Affairs, Senate Committee on Veterans' Affairs, Congressional Defense Committees
Where it stands
14 cosponsors: 12 Republicans, 2 Democrats.
- Mar 6, 2025 — Introduced · Congress.gov: “Introduced in House”
- Mar 6, 2025 — Referred to House Committee on Veterans' Affairs and House Committee on Armed Services · Congress.gov: “Referred to the Committee on Armed Services, and in addition to the Committee on Veterans' Affairs, for a…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $310,451 in lobbying spend. A filing names 170 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Scott Perry, the sponsor, reported $668,994 in PAC receipts in the 2026 cycle.
- Disabled American Veterans — $310,451 on 2 filings
Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (3,846 characters) on Sep 7, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,398 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 21, 2026 · page rendered 2026-10-23.
“VA and DoD ordered to offer experimental nerve-block PTSD treatment to veterans” QuorumCivic. https://share.quorumcivic.app/bill/119/hr1947 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.